VANCOUVER, British Columbia, Oct. 14, 2026 (GLOBE NEWSWIRE) -- MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF) (the “Company” or “MindBio”), a biotechnology company advancing the commercialisation of AI-driven voice analytics for drug and alcohol intoxication detection, is pleased to announce that it has completed the manufacture of its next-generation Edge AI Intoxication Detection Kiosk.

The newly manufactured hardware kiosk improves on an initial prototype produced in June this year. The new hardware is designed to support MindBio's proprietary Voice AI intoxication detection technology. The Company is continuing to refine, integrate and test its software, which analyses characteristics of the human voice to predict potential impairment associated with drug and alcohol consumption.

MindBio is working towards completion of software integration and system testing in preparation for initial commercial piloting, representing a significant step in the Company's transition from technology development towards real-world commercial validation.

Targeting a Scalable, Non-Invasive Alternative to Conventional Drug and Alcohol Testing

MindBio's Edge AI Intoxication Detection Kiosk is being developed to provide a rapid, non-invasive and scalable approach to screening for potential drug and alcohol intoxication using artificial intelligence and voice analytics.

The Company continues to test and validate its predictive AI models against established drug and alcohol testing methods, including breath alcohol testing and oral fluid (cheek swab) testing, with the objective of evaluating the technology's accuracy, reliability and suitability for commercial applications.  

MindBio is targeting industries where workplace safety, regulatory obligations and the need for large-scale drug and alcohol screening create significant operational and financial challenges. These include mining, aviation, construction, heavy transport, law enforcement and other safety-critical environments.

Traditional drug and alcohol testing methods can be labour-intensive, time-consuming, physically invasive and expensive to administer at scale. These challenges become particularly significant in industries employing large workforces that require regular or high-volume screening.

MindBio believes its Voice AI technology has the potential to transform workplace intoxication screening by enabling organisations to assess larger numbers of individuals more efficiently, at a potentially lower cost and with minimal physical intervention.

The Company's longer-term vision is to deliver an accessible, AI-powered screening solution that can be deployed across multiple workplace environments, supporting more frequent screening, improved operational efficiency and enhanced workplace safety.

By reducing the time, cost and logistical barriers associated with conventional testing, MindBio aims to make intoxication risk screening more accessible and scalable, ultimately contributing to the prevention of workplace accidents and injuries associated with drug and alcohol impairment.

MindBio's Chief Executive Officer, Justin Hanka, commented:

“We are making significant progress towards delivering an integrated hardware and software solution that has the potential to fundamentally change how organisations approach drug and alcohol intoxication screening.

“Our focus is on developing technology that can be deployed at scale, enabling businesses to screen more people, more frequently, in a fraction of the time and potentially at a significantly lower cost than conventional testing methods.

“The completion of our next-generation Edge AI Kiosk is an important milestone. We are now focused on validating our prediction models, integration of software and progressing towards a potential first commercial pilot later this year, where we intend to further evaluate the technology in a real-world operating environment against existing on-site testing methods.

“Our ambition is to develop a commercially scalable technology that not only addresses a significant global market opportunity but also helps organisations create safer workplaces and ultimately save lives.”

For further information, please contact:

Justin Hanka, Chief Executive Officer
+61 433140886
justin@mindbiotherapeutics.com
www.mindbiotherapeutics.com

About MindBio Therapeutics Corp.

MindBio is a biotechnology company that is commercialising AI prediction technologies for drug and alcohol intoxication detection via voice analysis. The AI prediction model analyses the human voice against millions of data points to detect drug and alcohol consumption. The Company is developing an enterprise platform including Edge-AI kiosks integrating bespoke hardware and software for the detection of drug and alcohol intoxication using the human voice and AI in a range of enterprise environments including the mining industry, aviation, construction and law enforcement.

Cautionary Note Concerning Forward-Looking Statements:

The press release contains “forward-looking statements” within the meaning of applicable securities laws, including but not limited to, the Company’s ability to complete the Offering and option grants on the terms announced, and the development of its enterprise platform using voice and powered by AI for use in detecting drug and alcohol intoxication. Forward-looking statements can be identified by words such as: “anticipate,” “intend,” “plan,” “budget,” “believe,” “project,” “estimate,” “expect,” “scheduled,” “forecast,” “strategy,” “future,” “likely,” “may,” “to be,” “could,” “would,” “should,” “will” and similar references to future periods or the negative or comparable terminology, as well as terms usually used in the future and conditional. Forward-looking statements are based on assumptions as of the date they are provided. However, there can be no assurance that such assumptions will reflect the actual outcome of such items or factors.

Additionally, there are known and unknown risk factors that could cause the Company’s actual results and financial conditions to differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important risk factors that could cause actual results and financial conditions to differ materially from those indicated in the forward-looking statements, include among others: the risk that the Company may not be able to raise the gross proceeds of the Offering; the failure to obtain the final regulatory approval; and technical challenges in the development or deployment of its enterprise platform; general economic, market and business conditions in Canada and Australia; market volatility; and unforeseen delays in timelines for any of the transactions or events described in this press release. All forward-looking information is qualified in its entirety by this cautionary statement.

The Company disclaims any obligation to revise or update any such forward-looking statement or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.

Neither the Canadian Securities Exchange nor its Regulation Service Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of the information in this press release.